ABVC BioPharma (ABVC) Stock Price, News & Analysis

Company Overview

ABVC BioPharma, Inc. is a clinical-stage biotechnology company developing pharmaceutical and diagnostic products. The company focuses primarily on therapies for central nervous system disorders, oncology and ophthalmic conditions, using a combination of internal research, licensing arrangements and collaborations with academic and industry partners.

ABVC’s development portfolio includes investigational treatments for conditions such as depression, attention-deficit/hyperactivity disorder, pancreatic cancer and certain eye diseases. Its programs are at various stages of preclinical and clinical development, and the company’s activities include advancing candidates through clinical trials, regulatory processes and potential commercialization.

Based in Fremont, California, ABVC has business and research connections in the United States and Taiwan. The company was previously known as American BriVision (Holding) Corp. before adopting the ABVC BioPharma name. As a development-stage biotechnology company, its products remain subject to clinical, regulatory and commercial risks before they can become broadly available.

Key Stats

• Today's Range: $0.96 to $1.03
• 50-Day Range: $0.71 to $1.16
• 52-Week Range: $0.71 to $3.07
• Volume: 55,896 shs
• Average Volume: 106,967 shs
• Market Capitalization: $27.22 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

ABVC BioPharma Stock Analysis - MarketRank™

ABVC BioPharma scored higher than 15% of companies evaluated by MarketBeat, and ranked 835th out of 873 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

ABVC BioPharma has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

ABVC BioPharma has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of ABVC BioPharma is -3.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of ABVC BioPharma is -3.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

ABVC BioPharma has a P/B Ratio of 1.90. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.27% of the float of ABVC BioPharma has been sold short.

Short Interest Ratio / Days to Cover

ABVC BioPharma has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in ABVC BioPharma has recently decreased by 2.89%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

ABVC BioPharma does not currently pay a dividend.

Dividend Growth

ABVC BioPharma does not have a long track record of dividend growth.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: N/A

News Sentiment

ABVC BioPharma has a news sentiment score of 1.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.71 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for ABVC BioPharma this week, compared to 1 article on an average week.

MarketBeat Follows

1 people have added ABVC BioPharma to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, ABVC BioPharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

19.00% of the stock of ABVC BioPharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

11.38% of the stock of ABVC BioPharma is held by institutions.

Company Calendar

• Last Earnings: 8/12/2026
• Today: 10/14/2026
• Next Earnings (Estimated): 11/16/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:ABVC
• CIK: 1173313
• Web: www.abvcpharma.com
• Phone: (510)-668-0881
• Fax: N/A
• Employees: 19
• Year Founded: 2002

Profitability

• EPS (Trailing Twelve Months): ($0.30)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$7.91 million
• Net Margins: N/A
• Pretax Margin: -954.77%
• Return on Equity: -47.68%
• Return on Assets: -30.97%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.07
• Quick Ratio: 0.07

Sales & Book Value

• Annual Sales: $510 thousand
• Price / Sales: 53.38
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.52 per share
• Price / Book: 1.96

Miscellaneous

• Outstanding Shares: 26,690,000
• Free Float: 21,622,000
• Market Cap: $27.22 million
• Optionable: Not Optionable
• Beta: 0.51